NVO Financials: Novo Nordisk A/S AI Analysis



Financials

NVO Financial

Novo Nordisk A/S

$46.52

1.4%

$0.64

At close: Jun 25, 16:00:00 GMT-4

$46.52

Post-market: Jun 25, 16:21:54 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$45.88

Open

$46.8

Day's Range

$46.44 - $47.12

52 week range

$35.12 - $71.8

Volume

9.3M

Avg.Volume

15.4M

Dividend yield

EPS (TTM)

4.27

Market Cap

$156.0B

What is Novo Nordisk A/S?

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	327,800	96,823	79,144	74,976	76,857	78,087
Revenue Growth (YoY)	8%	24%	-8%	5%	13%	19%
Cost of Revenue	59,496	13,598	15,148	17,904	12,846	12,890
Gross Profit	268,304	83,225	63,996	57,072	64,011	65,197
Selling, General & Admin	67,384	13,217	17,438	17,880	18,849	16,112
Research & Development	52,015	10,284	14,648	15,393	11,690	10,308
Operating Expenses	119,819	23,607	32,260	33,390	30,562	26,406
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	155,679	62,172	34,185	25,517	33,805	37,033
Income Tax Expense	33,722	13,615	7,294	5,511	7,302	7,999
Net Income	121,957	48,557	26,891	20,006	26,503	29,034
Net Income Growth	17%	67%	-5%	-27%	32%	14%
Shares Outstanding (Diluted)	4,450.68	4,450.68	4,452.15	4,446.8	4,446.7	4,446.24
Shares Change (YoY)	0%	0%	0%	0%	0%	-1%
EPS (Diluted)	27.41	10.91	6.04	4.5	5.96	6.53
EPS Growth	17%	67%	-5%	-26%	33%	15%
Free Cash Flow	31,029	12,045	-36,218	30,692	24,510	10,005
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	81.84%	85.95%	80.86%	76.12%	83.28%	83.49%
Operating Margin	45.29%	61.57%	40.09%	31.58%	43.52%	49.67%
Profit Margin	37.2%	50.15%	33.97%	26.68%	34.48%	37.18%
Free Cash Flow Margin	9.46%	12.44%	-45.76%	40.93%	31.89%	12.81%
EBITDA	170,173	63,154	37,298	31,439	38,282	42,621
EBITDA Margin	51.91%	65.22%	47.12%	41.93%	49.8%	54.58%
D&A For EBITDA	21,688	3,536	5,562	7,757	4,833	3,830
EBIT	148,485	59,618	31,736	23,682	33,449	38,791
EBIT Margin	45.29%	61.57%	40.09%	31.58%	43.52%	49.67%
Effective Tax Rate	21.66%	21.89%	21.33%	21.59%	21.6%	21.59%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

327,800

96,823

79,144

74,976

76,857

78,087

Revenue Growth (YoY)

24%

-8%

13%

19%

Cost of Revenue

59,496

13,598

15,148

17,904

12,846

12,890

Gross Profit

268,304

83,225

63,996

57,072

64,011

65,197

Selling, General & Admin

67,384

13,217

17,438

17,880

18,849

16,112

Research & Development

52,015

10,284

14,648

15,393

11,690

10,308

Operating Expenses

119,819

23,607

32,260

33,390

30,562

26,406

Other Non Operating Income (Expenses)

Pretax Income

155,679

62,172

34,185

25,517

33,805

37,033

Income Tax Expense

33,722

13,615

7,294

5,511

7,302

7,999

Net Income

121,957

48,557

26,891

20,006

26,503

29,034

Net Income Growth

17%

67%

-5%

-27%

32%

14%

Shares Outstanding (Diluted)

4,450.68

4,452.15

4,446.8

4,446.7

4,446.24

Shares Change (YoY)

-1%

EPS (Diluted)

27.41

10.91

6.04

4.5

5.96

6.53

EPS Growth

17%

67%

-5%

-26%

33%

15%

Free Cash Flow

31,029

12,045

-36,218

30,692

24,510

10,005

Free Cash Flow Per Share

Gross Margin

81.84%

85.95%

80.86%

76.12%

83.28%

83.49%

Operating Margin

45.29%

61.57%

40.09%

31.58%

43.52%

49.67%

Profit Margin

37.2%

50.15%

33.97%

26.68%

34.48%

37.18%

Free Cash Flow Margin

9.46%

12.44%

-45.76%

40.93%

31.89%

12.81%

EBITDA

170,173

63,154

37,298

31,439

38,282

42,621

EBITDA Margin

51.91%

65.22%

47.12%

41.93%

49.8%

54.58%

D&A For EBITDA

21,688

3,536

5,562

7,757

4,833

3,830

EBIT

148,485

59,618

31,736

23,682

33,449

38,791

EBIT Margin

45.29%

61.57%

40.09%

31.58%

43.52%

49.67%

Effective Tax Rate

21.66%

21.89%

21.33%

21.59%

21.6%

21.59%

Follow-Up Questions

What are Novo Nordisk A/S's key financial statements?



According to the latest financial statement (Form-10K), Novo Nordisk A/S has a total asset of $0, Net loss of $0

What are the key financial ratios for NVO?



Novo Nordisk A/S's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Novo Nordisk A/S's revenue broken down by segment or geography?



Novo Nordisk A/S largest revenue segment is Victoza, at a revenue of 3,020,000,000 in the most earnings release.For geography, US Revenue is the primary market for Novo Nordisk A/S, at a revenue of 173,166,000,000.

Is Novo Nordisk A/S profitable?



no, according to the latest financial statements, Novo Nordisk A/S has a net loss of $0

Does Novo Nordisk A/S have any liabilities?



no, Novo Nordisk A/S has liability of 0

How many outstanding shares for Novo Nordisk A/S?



Novo Nordisk A/S has a total outstanding shares of 0

Novo Nordisk A/S (NVO) Financial

NVO Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Novo Nordisk A/S?

Novo Nordisk A/S (NVO) Financial

NVO Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Novo Nordisk A/S?

NVO Income

Follow-Up Questions

What are Novo Nordisk A/S's key financial statements?

What are the key financial ratios for NVO?

How is Novo Nordisk A/S's revenue broken down by segment or geography?

Is Novo Nordisk A/S profitable?

Does Novo Nordisk A/S have any liabilities?

How many outstanding shares for Novo Nordisk A/S?